Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program

Overview

Journal Am J Gastroenterol

Specialty Gastroenterology

Date 2018 Oct 20

PMID 30337703

Citations 4

Authors

Akoi Koivogui

Guillaume Le Mab

Robert Benamouzig

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the change in the participation rate and the change in neoplasia incidence before and after the change of the Fecal Occult Blood Test (FOBT) in the cohort included in the Colorectal Cancer Screening Program (CRCSP).

Methods: Cohort of 279,210 people, aged 50-74 years, invited at least once before 2009, to participate in a CRCSP campaign. The participation rate and the cumulative neoplasia incidence were described on 4 campaigns (≤2008, 2009-2010, 2011-2012 and 2013-2014) with a Guaiac FOBT (gFOBT) and a first campaign (2015-2016) with a Fecal Immunochemical Test (FIT). The cumulative incidence was estimated by the actuarial method and its confidence interval by the Greenwood method.

Results: The participation rate decreased from 32.7% (first gFOBT-campaign) to 24.4% (fourth gFOBT-campaign) then, made a significant bound in the FIT-campaign (28.4%; p < 0.001). 35.4% of the 965 high-risk-polyps screened in this cohort were detected in the FIT-campaign. CRC incidence gradually decreased from 0.4 to 0.1/1000 person-years from the first to the fourth gFOBT-campaign before reaching a bound to 0.4/1000 person-years in the FIT-campaign.

Conclusion: Although it was still below the minimum European target (45%), the participation rate has increased between the last gFOBT-campaign and FIT-campaign, justifying the impact of promotional campaigns and the acceptance of the new test by people and GPs. A decline in the neoplasia incidence was observed between the initial and the fourth gFOBT-campaign. The change from gFOBT to FIT between the fourth and fifth campaigns, was associated with a significant increase in detection of neoplasia.

Citing Articles

Supply and quality of colonoscopy according to the characteristics of gastroenterologists in the French population-based colorectal-cancer screening program.

Koivogui A, Vincelet C, Abihsera G, Ait-Hadad H, Delattre H, Le Trung T World J Gastroenterol. 2023; 29(9):1492-1508.

PMID: 36998423 PMC: 10044857. DOI: 10.3748/wjg.v29.i9.1492.

Prediction of the severity of colorectal lesion by fecal hemoglobin concentration observed during previous test in the French screening program.

Balamou C, Koivogui A, Rodrigue C, Clerc A, Piccotti C, Deloraine A World J Gastroenterol. 2021; 27(31):5272-5287.

PMID: 34497450 PMC: 8384754. DOI: 10.3748/wjg.v27.i31.5272.

Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review.

Wang A, Lee B, Patel S, Whitaker E, Issaka R, Somsouk M J Med Screen. 2021; 28(4):379-388.

PMID: 33683155 PMC: 8423851. DOI: 10.1177/0969141321997482.

Colorectal cancer fecal screening test completion after age 74, sources and outcomes in French program.

Koivogui A, Balamou C, Rymzhanova R, Letrung T, Hadad H, Brixi Z World J Gastrointest Oncol. 2019; 11(9):729-740.

PMID: 31558977 PMC: 6755104. DOI: 10.4251/wjgo.v11.i9.729.

References

Liss D, Baker D . Understanding current racial/ethnic disparities in colorectal cancer screening in the United States: the contribution of socioeconomic status and access to care. Am J Prev Med. 2014; 46(3):228-36. DOI: 10.1016/j.amepre.2013.10.023. View

Kim D, Cha J, Kwak M, Yoon J, Cho Y, Jeon J . Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea. Gut Liver. 2017; 12(2):183-189. PMC: 5832343. DOI: 10.5009/gnl17030. View

Duncan A, Zajac I, Flight I, Stewart B, Wilson C, Turnbull D . Comparison of mailed invitation strategies to improve fecal occult blood test participation in men: protocol for a randomized controlled trial. Trials. 2013; 14:239. PMC: 3751457. DOI: 10.1186/1745-6215-14-239. View

Sieg A, Hertel A, John M, Luthgens K, Schmidt-Gayk H . Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev. 1998; 7(4):279-85. DOI: 10.1097/00008469-199808000-00003. View

Cha J, Lee J, Ro Joo K, Shin H, Park J . Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patients with a positive fecal immunochemical test. Dig Dis Sci. 2011; 56(11):3137-42. DOI: 10.1007/s10620-011-1720-0. View

Burnett-Hartman A, Mehta S, Zheng Y, Ghai N, McLerran D, Chubak J . Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med. 2016; 51(4):e107-15. PMC: 5030113. DOI: 10.1016/j.amepre.2016.02.025. View

Doorenbos A, Jacobsen C, Corpuz R, Forquera R, Buchwald D . A randomized controlled calendar mail-out to increase cancer screening among urban American Indian and Alaska Native patients. J Cancer Educ. 2011; 26(3):549-54. PMC: 5547754. DOI: 10.1007/s13187-011-0217-z. View

Weller D, Coleman D, Robertson R, Butler P, Melia J, Campbell C . The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 2007; 97(12):1601-5. PMC: 2360273. DOI: 10.1038/sj.bjc.6604089. View

Kronborg O, Jorgensen O, Fenger C, Rasmussen M . Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol. 2004; 39(9):846-51. DOI: 10.1080/00365520410003182. View

10.

van Rossum L, van Rijn A, Laheij R, van Oijen M, Fockens P, van Krieken H . Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135(1):82-90. DOI: 10.1053/j.gastro.2008.03.040. View

11.

Tazi M, Faivre J, Lejeune C, Benhamiche A, Dassonville F . [Performance of the Hemoccult test in the screening of colorectal cancer and adenoma. Results of 5 screening campaigns in Saône-et-Loire]. Gastroenterol Clin Biol. 1999; 23(5):475-80. View

12.

Center M, Jemal A, Smith R, Ward E . Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59(6):366-78. DOI: 10.3322/caac.20038. View

13.

Welch H, Robertson D . Colorectal Cancer on the Decline--Why Screening Can't Explain It All. N Engl J Med. 2016; 374(17):1605-7. DOI: 10.1056/NEJMp1600448. View

14.

Klabunde C, Shapiro J, Kobrin S, Nadel M, Zapka J . Colorectal Cancer Screening in US Seniors Ages 76-84 Years. J Community Health. 2015; 40(4):769-79. PMC: 4491009. DOI: 10.1007/s10900-015-9998-z. View

15.

Faivre J, Dancourt V, Lejeune C, Tazi M, Lamour J, Gerard D . Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004; 126(7):1674-80. DOI: 10.1053/j.gastro.2004.02.018. View

16.

Rabeneck L, El-Serag H, Davila J, Sandler R . Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). Am J Gastroenterol. 2003; 98(2):471-7. DOI: 10.1111/j.1572-0241.2003.07260.x. View

17.

von Karsa L, Patnick J, Segnan N . European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Executive summary. Endoscopy. 2012; 44 Suppl 3:SE1-8. DOI: 10.1055/s-0032-1309822. View

18.

Robertson D, Lee J, Boland C, Dominitz J, Giardiello F, Johnson D . Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2016; 112(1):37-53. DOI: 10.1038/ajg.2016.492. View

19.

Barton M . Physician-patient communication regarding colorectal cancer screening is lacking. CA Cancer J Clin. 2011; 62(1):1-2. DOI: 10.3322/caac.21130. View

20.

Altobelli E, Lattanzi A, Paduano R, Varassi G, Di Orio F . Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev Med. 2014; 62:132-41. DOI: 10.1016/j.ypmed.2014.02.010. View